2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

4:30PM-6:00PM: Abstract Number: 1916

The Interferon Gamma Release Assay Is a Novel Predictor of Disease Activity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Biomarkers

4:30PM-6:00PM: Abstract Number: 1924

The Nuclear Receptor ROR-Alpha As a Key Checkpoint of Tissue Repair

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 1877

The Performance of MRI Using the 3D Volumetric Interpolated Breath-Hold Sequence (VIBE) Technique to Detect Structural Changes in Patients with Early Axial Spondyloarthritis in Comparison to Conventional Radiography and Computed Tomography

Imaging of Rheumatic Diseases I: Novel Imaging and Scoring Systems

4:30PM-6:00PM: Abstract Number: 1919

The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Biomarkers

4:30PM-6:00PM: Abstract Number: 1881

The Utility of Autoimmune Serologies in Recurrent and Chronic Inflammatory Eye Disease

Miscellaneous Rheumatic and Inflammatory Diseases I

4:30PM-6:00PM: Abstract Number: 1878

The Utility of the Omeract Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials

Imaging of Rheumatic Diseases I: Novel Imaging and Scoring Systems

4:30PM-6:00PM: Abstract Number: 1882

Thymus and Activation-Regulated Chemokine (TARC) As Biomarker for IgG4-Related Disease

Miscellaneous Rheumatic and Inflammatory Diseases I

4:30PM-6:00PM: Abstract Number: 1906

Tofacitinib with and without Methotrexate Versus Adalimumab with Methotrexate for the Treatment of Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3b/4 Randomized Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Trials Therapy

4:30PM-6:00PM: Abstract Number: 1901

Unfavorable Body Composition Already at the Onset of Clinical Arthritis

Rheumatoid Arthritis – Clinical Aspects III: Obesity and Other Comorbidities

4:30PM-6:00PM: Abstract Number: 1921

Urine Angiostatin and VCAM-1 Surpass Conventional Metrics in Predicting Elevated Renal Pathology Activity Indices in Lupus Nephritis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Biomarkers

4:30PM-6:00PM: Abstract Number: 1866

Use of Aromatase Inhibitors and Risk of Arthritis and Musculoskeletal Problems Among Taiwanese Women with Breast Cancer: A Nationwide Claims Analysis

ACR/ARHP Combined: Epidemiology and Public Health: Prevention, Recognition, and Treatment

4:30PM-6:00PM: Abstract Number: 1858

Utilizing Needs Assessment Data to Establish Foundational Training for Adult and Pediatric Nurse Practitioners (NP) and Physician Assistants (PA) Entering Rheumatology Practice

ARHP Education/Community Programs

4:30PM-6:00PM: Abstract Number: 1870

Validation of an Electronic Version of the Michigan Body Map

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].